Analysts Set Masimo Co. (NASDAQ:MASI) Price Target at $143.57

Shares of Masimo Co. (NASDAQ:MASI) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $143.57.

Several brokerages recently commented on MASI. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. StockNews.com raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Stifel Nicolaus raised shares of Masimo from a “hold” rating to a “buy” rating and increased their price objective for the stock from $148.00 to $170.00 in a research report on Monday, April 15th. Piper Sandler raised shares of Masimo from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $126.00 to $160.00 in a research report on Monday, June 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, May 8th.

Insider Activity

In other news, Director Craig B. Reynolds sold 40,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $136.17, for a total value of $5,446,800.00. Following the completion of the transaction, the director now directly owns 7,406 shares in the company, valued at $1,008,475.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MASI. Riverview Trust Co bought a new position in Masimo during the 1st quarter valued at $25,000. Massmutual Trust Co. FSB ADV boosted its stake in Masimo by 140.6% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the last quarter. Byrne Asset Management LLC bought a new position in Masimo during the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC boosted its stake in Masimo by 851.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 264 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in Masimo during the 4th quarter valued at $36,000. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Performance

Shares of MASI stock opened at $131.17 on Friday. Masimo has a one year low of $75.22 and a one year high of $167.04. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.31 and a current ratio of 2.31. The company has a 50 day moving average price of $129.77 and a 200 day moving average price of $128.01. The firm has a market capitalization of $6.98 billion, a price-to-earnings ratio of 89.23 and a beta of 1.00.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, May 7th. The medical equipment provider reported $0.77 EPS for the quarter, topping the consensus estimate of $0.71 by $0.06. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The firm had revenue of $492.80 million during the quarter, compared to analyst estimates of $487.70 million. During the same quarter in the prior year, the business posted $0.87 earnings per share. Masimo’s revenue for the quarter was down 12.8% compared to the same quarter last year. Sell-side analysts anticipate that Masimo will post 3.63 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.